Analysts Set The Cooper Companies, Inc. (NASDAQ:COO) Price Target at $117.00

The Cooper Companies, Inc. (NASDAQ:COO) has received an average rating of “Moderate Buy” from the eleven ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $117.00.

A number of equities analysts have issued reports on COO shares. Wells Fargo & Company lifted their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, December 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. StockNews.com cut Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Citigroup cut their price target on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a report on Friday, December 6th. Finally, Morgan Stanley decreased their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th.

Hedge Funds Weigh In On Cooper Companies

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. boosted its stake in Cooper Companies by 23.0% during the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock valued at $435,856,000 after purchasing an additional 737,726 shares during the period. Franklin Resources Inc. boosted its position in shares of Cooper Companies by 194.0% during the third quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock worth $5,265,000 after buying an additional 32,260 shares during the period. Principal Financial Group Inc. grew its holdings in Cooper Companies by 6.6% in the 3rd quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock worth $26,295,000 after buying an additional 14,687 shares in the last quarter. Highland Capital Management LLC acquired a new stake in Cooper Companies in the 4th quarter valued at approximately $4,004,000. Finally, JPMorgan Chase & Co. raised its stake in Cooper Companies by 13.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock valued at $543,979,000 after acquiring an additional 573,908 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Stock Up 1.4 %

Shares of NASDAQ:COO opened at $96.67 on Monday. Cooper Companies has a 1-year low of $84.76 and a 1-year high of $112.38. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The stock has a market cap of $19.29 billion, a P/E ratio of 49.57, a P/E/G ratio of 2.45 and a beta of 1.00. The firm has a fifty day moving average price of $95.37 and a 200 day moving average price of $99.75.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.04. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. Cooper Companies’s revenue was up 9.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.87 EPS. Sell-side analysts predict that Cooper Companies will post 3.98 EPS for the current year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.